import nltk
nltk.download(['stopwords', 'punkt'])

from summarize import summarize
from data import data
import streamlit as st


st.write("""
#  Pharma Company POC
""")

st.sidebar.image("./NarrativaLogoBlanco.png")


def make_summarizing(new_body, hide=False, num_sentences=3):
    if hide:
        return ''
    result = summarize(
        new_body, sentence_count=num_sentences, language='english')
    return result


st.subheader("Overview")


st.write("""
         ##### Topics:
         - Cancer
         - immuno-oncology
         - New Therapy
         - BiTE
         """)
st.write("""
         ##### Summary:
         """)
st.write(make_summarizing(data["intro"]))
st.write('---')


st.write('##### Conversation:')
st.write("""
         
         ***Overview of the current therapeutic landscape for cancer and the immuno-oncology***
         
         """)
st.write(make_summarizing(data["block_1"]))


st.write("""
         
         ***How does the BiTE platform and constituent BiTE molecules actually work***
         
         """)
st.write(make_summarizing(data["block_2"], num_sentences=4))


st.write("""
         
         ***Where BiTE molecules are currently being studied***

         """)
st.write(make_summarizing(data["block_3"], num_sentences=3))


st.write("""
         
         ***Practial approach: Myeloma and BiTE***
         
         """)
st.write(make_summarizing(data["block_4"], num_sentences=6))


st.write("""
         
         ***Acute Myeloid Leukemia and BiTE molecules***

         """)
st.write(make_summarizing(data["block_5"], num_sentences=6))


st.write("""
         
         ***BiTE molecules for solid tumor types***

         """)
st.write(make_summarizing(data["block_6"], num_sentences=4))


st.write("""
         
         ***Takeaways***

         """)
st.write(make_summarizing(data["block_7"], num_sentences=3))


st.write("""
# MRD Slide Deck
""")
st.write("""
         ### Current Landscape in Minimal Residual Disease (MRD) Testing in Hematologic Malignancies
         """)


st.write("""
        - MRD is the presence of malignant cells under the detection limit of conventional methods
        - Strong prognostic indicator of patient outcomes
        - Potential for use in guiding treatment decisions
            - Intensity of therapy
            - Appropriateness of SCT
        - Currently measured using flow cytometry or qPCR
            - Newer testing methods are emerging
        - MRD is currently being evaluated as a potential surrogate endpoint, and may have the potential to replace or augment morphological CR as a response criteria in certain hematologic malignancies
        """)